Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004826|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : March 25, 2015
OBJECTIVES: I. Determine the efficacy and tolerability of clozapine in ameliorating psychosis in patients with idiopathic Parkinson's disease (PD).
II. Determine the adverse effects of clozapine on motor function in this patient population.
III. Determine the safety of clozapine in psychotic PD patients taking multiple anti-PD medications.
IV. Describe the phenomenology of drug induced psychosis in PD.
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Drug: clozapine||Not Applicable|
PROTOCOL OUTLINE: This is a randomized, placebo controlled, double blind study, followed by an open label treatment of all patients. Patients are stratified according to the institutional investigator and age.
In the first phase of the study, patients receive either clozapine or placebo. The drug is taken orally at night, approximately 30 minutes before retiring. Therapy continues for 4 weeks unless psychosis becomes unmanageable without hospitalization, parkinsonism worsens, or other adverse effects occur. It is possible that the dose may be escalated.
In the second phase of the study, all patients are treated with open label clozapine. Therapy continues for 3 months unless psychiatric status or parkinsonism progress. Dose escalation is also possible during this phase.
Patients are followed weekly during the first phase of the study, and monthly during the second phase.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Study Start Date :||October 1993|
|Study Completion Date :||November 1997|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004826
|Study Chair:||Joseph H. Friedman||Memorial Hospital of Rhode Island|